XML 57 R4.htm IDEA: XBRL DOCUMENT v3.22.4
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Revenue    
Research and development revenue under collaboration agreement $ 15,618 $ 30,985
Revenue from Contract with Customer, Product and Service [Extensible List] us-gaap:InProcessResearchAndDevelopmentMember us-gaap:InProcessResearchAndDevelopmentMember
Operating expenses    
Research and development $ 64,321 $ 47,108
General and administrative 22,201 18,015
Total operating expenses 86,522 65,123
Loss from operations (70,904) (34,138)
Other income (expense)    
Interest income 2,149 23
Other expense (10)  
Total other income, net 2,139 23
Net loss (68,765) (34,115)
Other comprehensive loss:    
Unrealized loss on marketable securities (763)  
Total comprehensive loss $ (69,528) $ (34,115)
Net loss per share:    
Net loss per share attributable to common stockholders basic $ (1.90) $ (1.22)
Net loss per share attributable to common stockholders diluted $ (1.90) $ (1.22)
Weighted-average common shares outstanding, basic 36,188,420 27,983,359
Weighted-average common shares outstanding, diluted 36,188,420 27,983,359